Professor Catriona Bradshaw [MMBS(Hons), FAChSHM, PhD] is a clinician researcher and Head of Research Translation and Mentorship and of The Genital Microbiota and Mycoplasma Group at Melbourne Sexual Health Centre, Central Clinical School, Monash University and Alfred Hospital and holds an honorary appointment at the University of Melbourne. Her programme focuses on translational research to improve treatment and control of STIs, including the development and implementation of resistance and point of care diagnostics, antimicrobial resistance and stewardship in STIs, and strategies to optimise reproductive health. Catriona is an NHMRC Leadership Fellow, a Centre Head for the Centre to Impact Antimicrobial Resistance (Monash University), and a Co-director of the ARC Research Hub to combat Antimicrobial Resistance (Monash/University of NSW/University of Queensland/industry/NGOs).  Catriona has a strong track record of translating findings into policy and practice with >320 publications (h-index 60; >13,000 citations), is a member of national and international STI guideline committees , a board member of the International Society for STD Research, a technical advisor for WHO, a past recipient of the L'Oréal-UNESCO Women in Science Award (2009) and of the Eureka Prize for Infectious Diseases (2022).

Catriona’s research has featured in the media including: The Age, The Australian, ABC AM, ABC/SBS/Channel 7 News, The Conversation, The New York Times, Herald Sun, Reuters, and The Weekly Review Magazine. She has recorded interviews on the ABC HealthReport and has been interviewed by Science journalists for the ABC, Australian Doctor, Medical Republic, Medical Observer and online forums such as Mamamia and Buzzfeed. Her research has featured on ABC radio and a number of community radio stations. She has been invited to present at forums to promote science for young women, gender equity in health and medical research and women in science in the corporate sector.

As a clinical researcher Catriona focuses on translational research to improve treatment and control of STIs, including the development and implementation of resistance and point of care diagnostics, antimicrobial resistance and stewardship in STIs, and strategies to optimise reproductive health. A major focus of work has been on Mycoplasma genitalium (MG), now considered an STI superbug, which is associated with serious sequelae in women and incurable infections are increasingly encountered. Her MG programme has been responsible for key advances that have provided new drug options and resistance-guided strategies which have been adopted internationally. Her current programme addresses urgent priorities to achieve and maintain high level cure and optimal antimicrobial stewardship and the development of surveillance systems to monitor AMR. Her programme of research on the vaginal microbiota has been focused on understanding the pathogenesis of the common dysbiosis, bacterial vaginosis, and developing interventions to improve long term cure and maintenance of a healthy vaginal microbiota to optimise reproductive health. Her group is currently undertaking an NHMRC funded multicentre male partner treatment trial for women with bacterial vaginosis and if effective this strategy will have a global impact providing opportunities for the 1st time for long-term control and prevention of BV and sequelae such as preterm birth. Both programmes have consistently influenced and changed policy and practice at a national and international level.